• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    SARS-CoV-2 R&D: Is It Over?

    Sustainability: A New Threat or Opportunity for CDMOs?

    Advanced Therapy Manufacturing

    Advanced Therapy Packaging Trends

    CEO Spotlight: Darren Head
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Piramal Pharma Solutions New API Plant in Canada Now Online

    MG America Appoints Claudio Radossi as President

    Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY

    Sartorius Expands Manufacturing Site in Tunisia

    BioMoti Partners with Pharma Company to Develop Ovarian Cancer Treatment
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Piramal Pharma Solutions New API Plant in Canada Now Online

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY

    Grand Opening of Kodiak Sciences’ Bioconjugation Facility

    Vertex Expands Cell and Gene Therapy Footprint
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    Royalty Pharma and Jefferies Invest $111M in ApiJect

    Cryoport Acquires Cell&Co BioServices for €6.2M

    Challenges of Developing Large Volume Drug/Device Combination Products for Parenteral SC Delivery

    Yourway Adds Capacity for Controlled Ambient Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    BioMoti Partners with Pharma Company to Develop Ovarian Cancer Treatment

    WCG Appoints Sam Srivastava CEO

    AffyXell Expands Manufacturing Partnership with GenScript ProBio

    ABL and Odimma Therapeutics Enter Development Agreement
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    FDA Inspection Trends Update

    Phase-Appropriate cGMP Considerations for Cell and Gene Therapy

    Sustainability: A New Threat or Opportunity for CDMOs?

    In Pursuit of Sustainability: How the Biopharma Industry Can Contribute

    Conducting Clinical Trials During the Pandemic: What Did We Learn?
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Quotient Sciences

    Aphena Pharma Solutions

    Baxter BioPharma Solutions

    Biosynth Carbosynth

    Qosina
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Quotient Sciences

    Aphena Pharma Solutions

    Baxter BioPharma Solutions

    Biosynth Carbosynth

    Qosina
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Expert's Opinion

    Exploring Potential Benefits of Outcomes-Based Contracts

    Achieving a successful transition, the benefits, potential downside, and looking forward

    Related CONTENT
    • Pharma Manufacturing: Methods for Real-Time Microbiology
    • Catalent, Acura Enter Clinical Manufacturing Pact
    • Leveraging Machine Learning and AI in Clinical Research
    • Growth in Biologics and Maintaining Patient Satisfaction
    • Lonza Expands Bioconjugation Facility and Third Commercial ADC Approved
    Dean Erhardt, President and CEO, D2 Consulting 09.25.19
    As policymakers and payers continue to make the shift from fee-for-service toward value-based approaches, it’s clear that hold-outs against this trend will have the most to lose in terms of missed opportunity.  

    Value-based purchasing encourages providers to participate in risk-bearing arrangements and implement programs that base Medicare reimbursement on patient clinical outcomes measures, such as hospital readmission rates. Similarly, private payers have implemented performance-based incentive programs and risk-sharing arrangements for hospitals and physicians.

    Adopting value-based strategies requires adaptability, knowledge of strategies and, in most cases, guidance when it comes to for successful negotiations that respond to changes resulting from regulatory and market pressures. The overall goal is to reduce cost without compromising safety and quality. 
     
    Achieving a Successful Transition
    The key to success lies in optimizing a strategy to show the value of a product to each health plan/payer in a way that sidesteps risk and drives optimal reimbursement. Therefore, it’s important to understand the impact of bundled payments, accountable care, comparative effectiveness research (CER), evidence-based medicine (EBM) and payments linked to performance. Complex regulatory issues must also be addressed in order to successfully negotiate value-based payment models.
     
    Stakeholders should seek a commercial services partner with expertise in the legal and business details surrounding commercial or government arrangements for payers. The right partners can also guide manufacturers on how to demonstrate flexibility and communicate their understanding and appreciation of stakeholder expectations.
     
    Value-based contracting represents an opportunity but stakeholders must first seek the knowledge, expertise and experience they need to achieve measurable results.
     
    The Benefits ofOutcomes-Based Contracts
    High drug prices have sparked increased interest in outcomes-based contracts, which tie rebates and discounts for expensive pharmaceutical products to the outcomes observed in the patients and make it possible for insurers and health care systems to improve value. Under these contracts, purchasers pay more for a drug when it effectively leads to improved outcomes and less when it falls short of expectations.

    Under an outcomes-based contract between a pharmaceutical manufacturer and a payer, reimbursement for a drug is based in part on outcomes of the drug’s use in a patient population. Instead of the payer covering all prescriptions at a single price, the initial price remains if a specified percentage of patients achieves the determined outcome. Conversely, if the outcome goal is not met, the manufacturer refunds some of the original price to the payer.
    Payers are able to prevent wasted resources on expensive drugs that fail to translate in the real world.

    Pharmaceutical manufacturers and purchasers have an opportunityto provide an alternative option to closed formularies, in which drugs can remain on the formularies in exchange for outcomes guarantees. In such cases, manufacturers retain sales volume and purchasers share the risk of low-value spending with manufacturers. This can lead to increased coverage of medicines for patients. 

    Potential Downside
    Keep in mind thatoutcomes-based contracts don’t apply to most drugs in the near term because of outcomes measurement limitations, and electronic health records and lab values that remain difficult to access for analysis.

    Some payersstate they have negotiated meaningful rebate differences in outcomes-based contracts—creating the potential for real savings. On the other hand, some payers state that the rebates they would receive for unmet outcomes would fail to offset the increase in costs associated with collecting and analyzing the data. Because brand-name pharmaceutical manufacturers set the price of their drugs under market conditions, they can raise a drug’s initial price to account for the possibility of an outcomes-based rebate.

    Despite rebate levels, contracts would not affect patient out-of-pocket costs. Patient costs occur at the point of sale, while the contracts provide retrospective rebates from manufacturers to the payers that might be calculated months after the prescription is filled. As outcomes-based contracts build momentum, it will be important to consider potential ways to allow patients to share in the savings.

    Outcomes-based pharmaceutical contracts could potentially move spending toward more effective treatments, but they are not likely to lower spending on a broad scale, given the limits on their applicability and meaningful metrics. The contracts apply only to a limited subset of drugs and are mostly linked to measures that do not directly reflect patient health outcomes.

    Looking Forward
    It’s possible that Medicare or Medicaid would consider outcomes-based pharmaceutical contracts, especially if tested in arrangements through the Center for Medicare and Medicaid Innovation. For now, political backlash against outcomes-based contracts remains staunch. Going forward, possible outcomes-based contracts tested under Medicare Part D should be independent of other potential changes in pharmaceutical reimbursement, such as direct pricing reform.

    In the case of contracts between manufacturers and health plans that include private plans administering Medicaid and Medicare, price and health outcomes data would need to be kept confidential but rigorously and independently analyzed. Also, an outcomes-based contracting pilot would have to be voluntary until more public information on its implications becomes available.

    Inevitably, as interest in value or outcomes-based pharmaceutical contracts grows, questions will revolve around their ability to effectively improve quality or generate true savings. Testing outcomes-based contracts in Medicare and Medicaid populations could serve as the first significant step toward determining whether the contracts can create real improvements in the value of pharmaceutical care.



     
    Dean Erhardt offers over 20 years of strategic marketing and management experience across both the consumer product and pharmaceutical arenas.  His areas of expertise include analysis and development of pharmaceutical support programs, pharmaceutical and consumer product distribution, and specialty pharmaceutical product management.  Mr. Erhardt’s experience has spanned several Fortune 500 organizations including Express Scripts, Cardinal Health and U.S. Healthcare. Currently, Mr. Erhardt supports companies in the launching and reimbursement of pharmaceutical, biotech and device products across the Specialty Pharmacy, Specialty Distribution, Retail, Long-Term Care, and Hospital Markets including limited and exclusive distribution models requiring REMS.  Additionally, Dean leads the D2 efforts in working with companies addressing Managed Care and Government payer market access issues. 
    Related Searches
    • Testing
    • patients
    • marketing
    • quality
    Suggested For You
    Pharma Manufacturing: Methods for Real-Time Microbiology Pharma Manufacturing: Methods for Real-Time Microbiology
    Catalent, Acura Enter Clinical Manufacturing Pact Catalent, Acura Enter Clinical Manufacturing Pact
    Leveraging Machine Learning and AI in Clinical Research Leveraging Machine Learning and AI in Clinical Research
    Growth in Biologics and Maintaining Patient Satisfaction  Growth in Biologics and Maintaining Patient Satisfaction
    Lonza Expands Bioconjugation Facility and Third Commercial ADC Approved Lonza Expands Bioconjugation Facility and Third Commercial ADC Approved
    La Jolla Pharma Receives Orphan Designation for Malaria Treatment La Jolla Pharma Receives Orphan Designation for Malaria Treatment
    Takeda Takeda
    GlaxoSmithKline GlaxoSmithKline
    Hoth Signs Contract Service Pacts for BioLexa Hoth Signs Contract Service Pacts for BioLexa
    Otsuka Chemical Enters API Business Otsuka Chemical Enters API Business
    Serialization and the Rest of Us Serialization and the Rest of Us
    Camargo to Acquire InSymbiosis Camargo to Acquire InSymbiosis
    Alector, Lonza Partner for Mfg. of Neurodegeneration Therapies Alector, Lonza Partner for Mfg. of Neurodegeneration Therapies
    Ology Wins Two DoD Awards Ology Wins Two DoD Awards
    Bosch Packaging Technology Hosts Pharmatag 2019 Bosch Packaging Technology Hosts Pharmatag 2019

    Related Content

    • Microbiology | QA/QC
      Pharma Manufacturing: Methods for Real-Time Microbiology

      Pharma Manufacturing: Methods for Real-Time Microbiology

      Vicki Barbur of Battelle discusses real-time microbiology, critical factors determining the rapid method of choice, and accessibility to new technologies
      Kristin Brooks, Contract Pharma 09.16.19

    • Breaking News | Collaborations & Alliances | Industry News | Scale-up/Technology Transfer
      Catalent, Acura Enter Clinical Manufacturing Pact

      Catalent, Acura Enter Clinical Manufacturing Pact

      Catalent to scale-up manufacturing of LTX-03 for clinical testing
      09.16.19

    • Clinical Trials | Information Technology | R&D
      Leveraging Machine Learning and AI in Clinical Research

      Leveraging Machine Learning and AI in Clinical Research

      New streams of real-world data from electronic health records and other data sources, with advances in ML, will be crucial for creating next-gen clinical trials
      Jennifer Bradford, Ph.D., Head of Data Science at PHASTAR 08.19.19


    • Biologics, Proteins, Vaccines | Drug Delivery | Injectables
      Growth in Biologics and Maintaining Patient Satisfaction

      Growth in Biologics and Maintaining Patient Satisfaction

      Vicki A. Barbur of Battelle discusses the driving forces for biologics, the challenges, and new delivery methods
      Kristin Brooks, Contrct Pharma 08.09.19

    • Biologics, Proteins, Vaccines | Industry News
      Lonza Expands Bioconjugation Facility and Third Commercial ADC Approved

      Lonza Expands Bioconjugation Facility and Third Commercial ADC Approved

      Expansion of bioconjugation in Visp to meet increasing clinical, launch and commercial market demand
      07.24.19

      Trending
      • Catalent Invests $175M To Expand Mfg. Capabilities At Winchester, KY | Contract Pharma
      • Sartorius Expands Manufacturing Site In Tunisia | Contract Pharma
      • Grand Opening Of Kodiak Sciences’ Bioconjugation Facility | Contract Pharma
      • Vertex Expands Cell And Gene Therapy Footprint | Contract Pharma
      • Emergex COVID-19 Vaccine Candidate Successfully Coated Onto Zosano Micro-Needle Patch | Contract Pharma
      Breaking News
      • Piramal Pharma Solutions New API Plant in Canada Now Online
      • MG America Appoints Claudio Radossi as President
      • Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY
      • Sartorius Expands Manufacturing Site in Tunisia
      • BioMoti Partners with Pharma Company to Develop Ovarian Cancer Treatment
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Sustainability and the Biopharma Industry
      • Contract Manufacturing During COVID
      • Orphan Drugs in the United States
      • CEO Spotlight: Peter DeYoung
      • CEO Spotlight: Darren Head
      • Advanced Therapy Packaging Trends
      • Advanced Therapy Manufacturing
      • Sustainability: A New Threat or Opportunity for CDMOs?
      • SARS-CoV-2 R&D

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      GOED Creates Infographic Highlighting Omega-3 Health Claims Approved in Europe
      Kyowa Hakko Appoints Dr. Colin Hill to Immuse Scientific Advisory Board
      Expert Consensus Statement: Diet is Best Primary Intervention to Achieve Diabetes Remission
      Coatings World

      Latest Breaking News From Coatings World

      Teknos Receives EcoVadis Gold Medal for Sustainability Performance
      AkzoNobel and Partners Team Up to Hack Carbon Reduction Challenges
      Five PPG Facilities in Ohio Recognized for Sustainability, Health, Safety Practices
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      Iterative Scopes Expands its Senior Leadership Team
      Viz.ai Raises $100 Million in Series D Funding
      FDA Clears Arterys' AI Mapping and Quantification Tools
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Piramal Pharma Solutions New API Plant in Canada Now Online
      MG America Appoints Claudio Radossi as President
      Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Authentic Beauty Concept Launches Second-Generation ‘Refill Bar’
      HASK Beauty Enters Exclusive Partnership with Amazon
      Garance Doré Launches Made in France Skincare Line
      Happi

      Latest Breaking News From Happi

      SPF Setting Spray, Lip Contour and Knotless Braids Are Hot Trends: Spate
      Nutrafol Launches Collagen Infusion
      ÄZ Craft Luxury Haircare Products Support All Hairstyles
      Ink World

      Latest Breaking News From Ink World

      Nazdar Celebrates 100 Years with a New Look
      hubergroup Chemicals Exhibits at Paint India for First Time
      Award for Sustainability: Evonik Receives Platinum Rating Again
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Specialty announces move to new facility
      Mark Andy hosts dealer's open house in Warsaw
      Nazdar celebrates 100th anniversary with refreshed brand identity
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      3M to Expand in Nebraska
      Nicely Offers Nonwoven Slitters, Winders
      'Right' Hygiene Conference to be Held in June
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      FDA Clears Anika Therapeutics' X-Twist Knotless Fixation System
      Paragon 28 Rolls Out TenoTac 2.0 Hammertoe and Soft Tissue Repair
      Cionic Expands Scientific Advisory Board
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Evonik Launches New Processing Aids for PV Wafer Cutting
      NREL Creates Highest Efficiency 1-Sun Solar Cell
      eMagin Wins People’s Choice Award at Display Week 2022

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login